| 21.903 0.343 (1.59%) | 01-21 10:22 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 26.99 |
1-year : | 31.52 |
| Resists | First : | 23.1 |
Second : | 26.99 |
| Pivot price | 20.64 |
|||
| Supports | First : | 20.08 |
Second : | 18.2 |
| MAs | MA(5) : | 20.41 |
MA(20) : | 20.94 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.4  |
| %K %D | K(14,3) : | 54.2 |
D(3) : | 43.4 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 23.14 | Low : | 13.35 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LBRX ] has closed below upper band by 23.8%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 22.68 - 22.79 | 22.79 - 22.89 |
| Low: | 19.15 - 19.27 | 19.27 - 19.36 |
| Close: | 21.38 - 21.57 | 21.57 - 21.73 |
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Tue, 13 Jan 2026
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Thu, 06 Nov 2025
LB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate Updates - GlobeNewswire
Tue, 16 Sep 2025
Vida Ventures raises $5.0m in LB Pharmaceuticals (LBRX) - Investing.com
Fri, 12 Sep 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering - Mintz
Wed, 10 Sep 2025
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering - GlobeNewswire
Tue, 09 Sep 2025
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 25 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 97.3 (%) |
| Shares Short | 1,830 (K) |
| Shares Short P.Month | 243 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -29.14 |
| PEG Ratio | 0 |
| Price to Book value | 1.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -23.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|